posted on 2021-11-30, 16:37authored byWeijun Wei, Di Zhang, Cheng Wang, You Zhang, Shuxian An, Yumei Chen, Gang Huang, Jianjun Liu
Noninvasive diagnosis of multiple
myeloma (MM) is a clinical challenge.
CD38 is an established biomarker for MM, and the development of CD38-targeted
radiotracers may improve the management of MM. By taking the advantages
of bioorthogonal click chemistry, a nanobody (i.e., Nb1053-LLQS) specific
for CD38 was successfully labeled with 18F. The diagnostic
efficacy and specificity of the developed tracer (i.e., [18F]F–Nb1053) were evaluated by immuno-positron emission tomography
(immunoPET) imaging in disseminated MM.1S-bearing models. [18F]F–Nb1053 was developed with high radiochemical purity (>98%)
and excellent immunoreactivity. [18F]F–Nb1053 immunoPET
successfully delineated disseminated MM lesions in preclinical MM
models. The uptake in the humerus, femur, and tibia was 1.42 ±
0.50%ID/g, 1.35 ± 0.53%ID/g, and 1.48 ± 0.67%ID/g (n = 6), respectively. Tumor uptake of [18F]F–Nb1053
decreased after daratumumab premedication, indicating the superior
specificity of the reported probe. This work successfully developed
a novel CD38-specific probe [18F]F–Nb1053 that may
potentially optimize the management of MM upon clinical translation.